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When  carefully  controlled  numbers  of alloantigenic  cells  are  injected  into  the 
anterior  chamber of the  eye,  they elicit  an  unconventional  host  immune  response. 
This  phenomenon,  first  described  in  a  rat  alloimmune  system  (1,  2),  has  been 
successfully adapted to mice. BALB/c mice, injected intracamerally with P815 tumor 
cells derived from the DBA/2 mouse strain, can be rendered specifically unresponsive 
to the minor histocompatibility antigens of the DBA/2 strain.  These animals accept 
orthotopic  DBA/2  skin  grafts  for prolonged  intervals  and  allow  P815  cells  to form 
tumors at subcutaneous inoculation sites. These findings confirm and extend evidence 
in favor of the hypothesis that alloantigenic presentation through the anterior chamber 
of the  eye  (and  perhaps  other  immunologically privileged  sites  as well)  induces  an 
active immune response that is protective rather than destructive. 
The P815 tumor cell line originated in the DBA/2 mouse strain.  Cells of this line 
express surface histocompatibility  antigens  as well  as tumor-specific transplantation 
antigens  (3).  P815 has been used extensively to study alloimmune reactions  in vitro, 
especially cytolytic reactions. The DBA/2 and BALB/c mouse strains are related  to 
each  other  in  that  both  share  the  same H-2  chromosomal segment;  however,  they 
differ at multiple minor histocompatibility loci (4).  Their minor alloantigenic dispar- 
ities were used to advantage in this study. 
Materials  and Methods 
Experimental Animals.  Adult female BALB/c (H-2 a) and DBA/2 (H-2 a) mice were purchased 
from The Jackson Laboratory, Bar Harbor, Maine and used as experimental  subjects when 
they were between 3 and 5 mo of age. 
Tumor Cells.  P815 mastocytoma (DBA/2) cells were cultivated  in suspensions cultures in 
Falcon 75-cm  ~ tissue culture flasks  (Falcon Labware Div., Beeton, Dickinson & Co., Oxnard, 
Calif.)  using Dulbeeeo's modified Eagle's minimal essential  medium supplemented  with  10% 
heat-inactivated fetal calf serum and gentamycin (0.05 mg/ml; Sehering Corp., Kenilworth, N. 
J.). EL-4 lymphoma (C57BL/6) was maintained by serial  passage as ascites in C57BL/6 mice. 
Monocellular suspensions of P815 cells  and EL-4 cells were washed  in Hanks' balanced salt 
solution (HBSS) and resuspended in HBSS for subcutaneous and intracameral inoculations. 
Anterior Chamber Inoculations.  A  modified quantitative  technique  for depositing a  definite 
number of tumor cells into the anterior chamber of the mouse eye was employed (5). Mice were 
deeply anesthetized  with  0.66 mg of ketamine  hydroehloride  (Vetalar;  Parke,  Davis & Co., 
Detroit,  Mich.)  given intramuscularly.  The eye was viewed under the low power (8 ×) of a 
dissecting microscope and  a  sterile  30-gauge needle was used to puncture the cornea at  the 
corneoscleral junction, parallel and anterior to the iris. The aqueous humor was expressed by 
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compressing the cornea with the back of a scalpel blade and the evacuated fluid blotted with 
sterile gauze pads. A  micro-glass pipette (~80 #m  in diameter) was fitted into sterile infant 
feeding tube (5 French; Cutter Laboratories, Inc., Berkeley, Calif.) that was mounted onto a 
sterile 0. l-ml Hamilton syringe (Hamilton Co., Inc., Whittier, Calif.). A Hamilton automatic 
dispensing apparatus was fitted onto the loaded syringe and was used to dispense 5-/~1 quantities 
of P815 cell suspensions. The pipette loaded with P815 cell suspension (2 ×  107 cetls/ml --  1 
×  105 cells/5 ~1) was introduced through the puncture site of the cornea and 5 p.l of the P815 
cell suspension delivered into  the anterior chamber.  As the needle was withdrawn,  the  iris 
prolapsed and plugged the perforated cornea, thereby minimizing leakage of the inoculum. 
Subcutaneous Inoculations.  1 ×  105 tumor cells (P815 or EL-4) suspended in 0.1  ml of HBSS 
were inoculated subcutaneously into the right rear flanks. 
Skin  Grafting.  Full-thickness skin grafts were prepared as described elsewhere  (6).  Grafts 
were applied orthotopically and wrapped in plaster of Paris bandages. Casts were removed 7 d 
later, and the grafts inspected for evidence of rejection. Destruction was judged complete when 
all remnants of surface epidermis were gone. Median survival times were calculated. 
Results 
P815 tumor cells, in a constant dose of 105/inoculum, were injected into the anterior 
chamber of eyes of panels of DBA/2 and BALB/c mice. A  typical growth pattern was 
observed  that  was  identical  for  members  of both  strains:  white  clumps  of tumor 
appeared in the anterior chamber within 4  to 5 d. Over the next  10 d, the chamber 
gradually filled with tumor which then grew anteriorly in wedge-shaped manner into 
the substance of the cornea and finally perforated that structure. These orbital tumors 
continued  to  grow  for  as  long  as  3  wk,  although  necrosis  frequently  intervened, 
destroying the inoculated eye. 
Comparable  numbers  of P815  cells were  then  injected  subcutaneously  into  the 
flanks of similar panels of DBA/2 and BALB/c mice. Progressively growing tumors 
appeared  at  inoculation  sites in  DBA/2  recipients, but  no  evidence of tumors  was 
found  in  the  flanks  of  BALB/c  recipients  (Table  I).  This  set  of  findings  clearly 
indicates that the anterior chamber of the mouse eye is an immunologically privileged 
site  that  allows  a  histoincompatible  tumor  cell  line  injected  therein  to  grow  un- 
impeded. 
Next,  a  panel of BALB/c  mice was  grafted orthotopically with °DBA/2  skin.  All 
grafts were rejected in typical first-set fashion, with a  median survival time of 10.8 d 
(Table II). 2 wk after engraftment, these animals received intracameral injections of 
105 P815 cells/eye. No evidence of tumor appeared in the injected eyes of any of these 
animals (Table I). This finding is consistent with the results of many previous studies 
(7)  which  document  that  a  pre-existing  state  of  alloimmunity  robs  the  anterior 
chamber of its capacity to act as an immunologically privileged site for alloantigenic 
tissues. 
TABLE  I 
Development of Local Tumors After Inoculation of PS15 Cells into BALB/c Recipients 
Pretreatment  Site of P815" Inoculation  Tumors/eyes injected 
1 None  Subcutaneous  0/10 
2 None  Anterior chamber  20/20 
3  DBA/2 Skin graft  Anterior chamber  0/20 
4  P815 injected intracamerally  Subcutaneous  20/20 intracameral 
10/10 subcutaneous 
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TABLE  II 
Influence of Intracameral Inoculation of P815 Cells on the Alloimmune Response of BALB/c Mice to 
D BA / 2 Minor A lloantigens 
Median survival time of 
Primary exposure to DBA/2 alloantigens  n  subsequent DBA/2 skin 
grafts* 
I  None (first set) 
2  DBA/2 skin allograft 
3  P815 cells injected subcutaneously 
4  P815 cells injected into anterior chambers of both eyes 
d 
lO  10.8 (m.2-i 1.8) 
10  7.0  (6.8-7.2) 
10  7.0  (6.5-7.5) 
8  >30, 
* Days +  95% confidence limits. 
:]: Only two recipients rejected DBA/2 grafts; the remaining grafts were healthy throughout observation 
interval. 
To  verify that  the  alloantigens  expressed  on  the  P815  tumor  were  capable  of 
inducing alloimmunity, normal BALB/c animals were injected subcutaneously with 
105 P815 cells.  2 wk later, these mice received orthotopic DBA/2 skin grafts. These 
grafts were rejected briskly, with a  median survival time of 7.0 d  (Table II). This is 
identical to the accelerated rejection observed in  BALB/c mice immunized with a 
primary DBA/2 skin graft (Table II). Thus, the P815 tumor cell line expresses DBA/ 
2-specific transplantation antigens in a  manner capable of eliciting specific alloim- 
munity. In an effort to understand the reason for the progressive growth of P815 cells 
in the anterior chamber of normal BALB/c mice, recipients of intracameral P815 
tumor cell injections were grafted orthotopically 2 wk later with DBA/2 skin grafts. 
As might have been predicted from our previous experience with a similar model in 
rats (2, 5, 6), these animals proved to be relatively-to-absolutely unresponsive to DBA/ 
2 alloantigens. The median survival time of DBA/2 skin grafts on BALB/c mice that 
bore  the  P815  tumor  in  the anterior chamber was >30  d  (Table  II).  Six of eight 
animals failed absolutely to reject their DBA/2 skin grafts during the 30-d observation 
period. 
Finally, BALB/c mice that were injected intracamerally on day 0 with P815 cells 
were  injected subcutaneously 5  d  later with  105  P815  cells.  Progressively growing 
subcutaneous tumors developed in all of these animals (Table I). In control experi- 
ments,  a  genetically dissimilar  tumor  cell  line,  EL-4  (derived  from  the  C57BL/6 
strain), was unable to influence in any way the immune reactivity of BALB/c mice to 
DBA/2 alloantigens. Thus, the intracameral presentation of the minor histocompat- 
ibility antigens of DBA/2 expressed on P815  tumor cells subverted the capacity of 
recipient  BALB/c  mice  to  mount  a  typical  immune  response  to  DBA/2  minor 
histocompatibility antigens. Indeed, these recipients permitted extended survival of 
both skin and tumor allografts. 
Discussion 
Since their experimental description >30 yr ago (8),  immunologically privileged 
sites  have  languished  at  the  periphery  of transplantation  immunobiology.  With 
relatively few exceptions, their investigation has been ignored by the immunological 
community. This relates partly to the fact that early studies ascribed the privileged 
state to the absence of lymphatic drainage routes  (7), which allowed the simplistic 1124  STREILEIN ET AL.  BRIEF  DEFINITIVE REPORT 
conclusion that antigens presented at sites of immunologic privilege escape detection 
by the immune system. More recent studies have indicated that this simple construc- 
tion  may  be  naive.  In  rats,  when  alloantigens  (displayed  on  lymphocytes  from 
semiallogeneic  F1  hybrids or on  tiny  skin  allografts)  are  placed  into  the  anterior 
chamber of the eye, they produce a  state of immune deviation in which prolonged 
survival of subsequent orthotopic skin grafts is observed (2, 9). It was also found that 
this state of specific immune deviation depended upon: (a) the persistence of antigen 
within the anterior chamber, and (b) the presence of an intact and functional spleen 
(5, 6). 
Further experimental analysis of the phenomenon in rats proved difficult because 
of limited availability of discriminating reagents and genetically defined allodisparate 
rat  strains.  As  a  consequence, the model was  adapted  for use in  mice. The results 
reported in this communication are the first to emerge from this successful adaptation. 
These findings verify the validity and generality of the original hypothesis: antigens 
presented  via  the  anterior  chamber  impact  the  immune  response  in  an  unusual 
fashion:  as a  consequence, the development of a  destructive response is subverted; 
instead, a protective one is elicited. Although much needs to be done to understand 
the cellular and molecular basis of the phenomenon, it is already clear that there are 
likely  to  be  important  ramifications.  We  believe  that  immunologic  privilege  as 
described for the brain, the anterior chamber of the eye, the hamster cheek pouch, 
and,  perhaps,  other  sites  should  no  longer  be  regarded  as  an  interesting,  albeit 
unimportant,  immunologic  phenomenon.  Rather,  understanding  the  basis  of this 
phenomenon holds considerable promise of yielding important  information in  the 
diverse fields of ocular immunology and transplantation biology. 
Summary 
The  ability  to  introduce  carefully  controlled  numbers  of viable  cells  into  the 
anterior chamber of mouse eyes made  it  possible to examine the  interrelationship 
between presentation of antigens  into the anterior chamber and  into conventional 
body  sites  and  their  synergistic/antagonistic  effects on  the  immune  system.  P815 
mastocytoma  (DBA/2;  H-2 a)  cells are syngeneic with  BALB/c hosts  at  the  major 
histocompatibility locus, but differ at multiple minor histocompatibility loci. When 
P815  cells were injected subcutaneously, they were rejected by BALB/c recipients 
who became specifically immune.  By contrast, when P815 cells were injected intra- 
camerally, they grew progressively into massive intraocular tumors; moreover, these 
BALB/c hosts  proved subsequently  unable  to reject subcutaneously  injected P815 
cells, and, more impressively, failed to reject DBA/2 skin allografts placed orthotop- 
ically. Minor histocompatiblity antigens, presented first through the anterior chamber 
of mouse eyes, elicit a suppressive rather than an agressive host immune response that 
protects cells that bear these antigens from a destructive alloimmune reaction at both 
intracameral and systemic sites. 
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